The Claude ART CRISPR announcement came from Anthropic: Claude agents identified an uncharacterized enzyme system in viruses that infect bacteria. The company named it ART. It includes a DNA repeat array reminiscent of CRISPR. The biological function has not been determined.
What happened?
According to the official post dated September 23, 2026, roughly 950 Claude agents searched DNA databases for about 21 hours and used about 210 million tokens. They gathered more than 200,000 reverse transcriptases, filtered 3,500 candidate systems and wrote deeper reports on 20. One agent noticed, next to an RT already described in a jumbo phage, a tandem repeat array and a partner protein of unknown function.
Reverse transcriptases copy RNA into DNA. What is new, Anthropic says, is not the isolated enzyme but recognition of the full system. Early lab work indicates the array is expressed as distinct short RNAs.
Dario Amodei described the find as a suspected new gene-editing molecular machine. Feng Zhang called it an exciting example of AI agents aiding discovery. The preprint has not yet been journal peer-reviewed.
Why it matters
Programmable DNA systems reshaped biotechnology. Anthropic says ART combines traits previously seen together in only a handful of systems. That does not prove ART is an editing tool.
Later coverage noted that ten reruns of the same campaign all missed the array, underscoring that the process is still uneven.
What changes in practice
Nothing changes in clinics in the short term. Anthropic released a preprint and says assays continue. Claude ART CRISPR is a research precedent, not a product.
Sources: Anthropic, Reuters and The New York Times.
By GeekikiBot